Cell Cycle Inhibitors: CDK4/6 Inhibitors
Treatment given for recurrence occurring at any time after last platinum-based treatment
Objective Response Rate (%)
Percentage of patients whose tumors shrink or go away after treatment
Progression Free Survival (months)
Median length of time before the cancer comes back or gets worse
Cell Cycle Inhibitors: CDK4/6 Inhibitors
Neo adjuvant (before surgery) and first-line treatment with/without extended (maintenance) treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT03531645 | II | Abemaciclib, Fulvestrant | A Pilot Phase II Study of Neoadjuvant Fulvestrant Plus Abemaciclib in Women With Advanced Low Grade Serous Carcinoma | Neoadjuvant treatment with fulvestrant and abemaciclib is tolerable and demonstrates unprecedented response and complete gross resection rates in Low Grade Serous OC ORR: 60% (n=15) 7 patients w/ IDS: |
Treatment given for recurrence occurring at any time after last platinum-based treatment
For more detailed information, please click on the clinical trial ID number.
| Trial ID # | Phase | Drugs | Clinical Trial Title | Key Conclusion and Results |
|---|---|---|---|---|
| Drugs in Clinical Development | ||||
| NCT01536743 | II | Palbociclib | A Open Label Phase II Study of the Efficacy and Safety of PD0332991 a Selective Inhibitor of the Cyclin Dependent Kinases 4 and 6 in Patients With Recurrent Ovarian Cancer Demonstrating Rb-proficiency and Low p16 Expression | Palbociclib has modest single agent activity in unselected patients, but shows encouraging activity in patients with CDKN2A loss or CDK6 AMP ORR: 6% 6 patients w/ response by CA125 or RECIST: abs Jun 2016 and poster |
| NCT02657928 | II | Letrozole, Ribociclib | A Phase 2 Trial of Ribociclib (LEE011) and Letrozole in ER Positive Relapsed Ovarian Cancer, Fallopian Tube Cancer, Primary Peritoneal Carcinomas, and Endometrial Cancers. | Ribociclib+letrozole is active in ER+ OC with 25% achieving PFS for 23 weeks or longer, but greatest benefit is seen in LGSOC ORR (HGSOC): 0% abs May 2019 and presentation |
| NCT03673124 | II | Letrozole, Ribociclib | A Phase II Trial of Ribociclib (LEE011) Plus Letrozole in Women With Recurrent Low-Grade Serous Carcinoma of the Ovary, Fallopian Tube or Peritoneum | The combination of letrozole plus ribociclib demonstrates promising activity in women with recurrent LGSOC ORR: 23% abs Mar 2023 and presentation |